AGP Picks
View all

Novaspira reports early Phase 1 data for GPC3x4-1BB bispecific in liver cancer

Nov. 7, 2026
By AI, Created 21:00 UTC, Nov 07, 2026, AGP -

Novaspira Biotherapeutics said early Phase 1 results for BOS-342, a GPC3x4-1BB bispecific, showed manageable safety and signs of durable activity in advanced hepatocellular carcinoma. The data were presented at the Society for Immunotherapy of Cancer meeting in Phoenix as the company prepares a new Phase 1 study across South Korea, Taiwan and the U.S.

Why it matters: - BOS-342 is aimed at a hard-to-treat liver cancer population that had already progressed on PD-(L)1 inhibitors and VEGF-targeted therapy. - The early data suggest tumor-directed 4-1BB activation may produce antitumor activity without the systemic immune toxicity that can limit other immunotherapies. - Novaspira is now moving the program into a new Phase 1 study across multiple countries.

What happened: - Novaspira Biotherapeutics presented first-in-human clinical data for BOS-342, also called NS-342, at the 41st Annual Meeting of the Society for Immunotherapy of Cancer in Phoenix, Arizona. - The late-breaking oral presentation was Abstract #1173 and was delivered by Hong Jae Chon, M.D., Ph.D., of CHA Bundang Medical Center. - The presentation covered safety, pharmacodynamic and clinical activity findings from an ongoing Phase 1 study in advanced hepatocellular carcinoma. - The presentation title was “A Phase I First-in-Human Study of BOS-342, a Novel GPC3 × 4-1BB Bispecific Molecule, in Advanced Hepatocellular Carcinoma: Early Report of Safety, Immune, Biochemical and Durable Clinical Responses.”

The details: - BOS-342 is designed to activate the costimulatory receptor 4-1BB only when GPC3-expressing tumor cells are present. - The goal is to keep immune activation inside the tumor microenvironment and reduce systemic toxicity. - Twelve patients with advanced HCC were treated with escalating single-agent doses every two weeks. - All patients had disease progression after prior PD-(L)1 inhibitors and VEGF-targeted therapy. - BOS-342 showed a manageable safety profile across all dose levels evaluated. - No dose-limiting toxicities were observed. - No Grade 4 or Grade 5 treatment-related adverse events were reported. - No cytokine release syndrome or immune-related adverse events were observed. - Infusion-related reactions were the most common treatment-related adverse event. - Those reactions were managed with premedication and infusion-rate modification. - At the highest dose level, the objective response rate was 28.6%, or 2 of 7 patients. - One patient had a durable partial response that has lasted more than 24 months and is still ongoing. - Across all dose levels, the 12-week disease control rate was 50%.

Between the lines: - The results add early clinical support for conditional, tumor-directed 4-1BB costimulation in hepatocellular carcinoma. - The combination of no cytokine release syndrome and no immune-related adverse events stands out in a field where safety often constrains dose and development speed. - The durable response in a heavily pretreated patient hints that the approach may have more than short-lived activity, but the sample size is still very small. - Novaspira is positioning NS-342 as part of the next wave of tumor-targeted immunotherapies rather than a broad immune activator.

What's next: - Novaspira said a new Phase 1 clinical study, NS-342-101, is being initiated in South Korea, Taiwan and the United States. - The company plans to present additional biomarker, immune pharmacodynamic and translational analyses at future scientific meetings. - Further evaluation in larger patient cohorts will be needed to define the full therapeutic potential of the approach. - NS-342 is also being developed for GPC3-positive solid tumors, including liver and lung cancers.

The bottom line: - Early human data suggest BOS-342 can be given safely and may generate durable responses in advanced liver cancer, but the program still needs larger studies to prove the signal holds up.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Health Daily South Korea

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Daily South Korea

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.